Cargando…
The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes
Glucagon-like peptide-1 receptor (GLP-1R) agonists are a class of newly introduced antidiabetic medications that potentially lower blood glucose by several molecular pathways. DPP-4 inhibitors are the other type of novel antidiabetic medications which act by preventing GLP-1 inactivation and thereby...
Autores principales: | Yaribeygi, Habib, Farrokhi, Farin Rashid, Abdalla, Mohammed Altigani, Sathyapalan, Thozhukat, Banach, Maciej, Jamialahmadi, Tannaz, Sahebkar, Amirhossein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263148/ https://www.ncbi.nlm.nih.gov/pubmed/34258291 http://dx.doi.org/10.1155/2021/6518221 |
Ejemplares similares
-
The Impact of Diabetes Mellitus in COVID-19: A Mechanistic Review of Molecular Interactions
por: Yaribeygi, Habib, et al.
Publicado: (2020) -
Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis
por: Yaribeygi, Habib, et al.
Publicado: (2020) -
Pathophysiology of Physical Inactivity-Dependent Insulin Resistance: A Theoretical Mechanistic Review Emphasizing Clinical Evidence
por: Yaribeygi, Habib, et al.
Publicado: (2021) -
Antioxidative Potentials of Incretin-Based Medications: A Review of Molecular Mechanisms
por: Yaribeygi, Habib, et al.
Publicado: (2021) -
The Emerging Role of Nanomedicine in the Management of Nonalcoholic Fatty Liver Disease: A State-of-the-Art Review
por: Moosavian, Seyedeh Alia, et al.
Publicado: (2021)